3 completed, 1 recruiting, 1 terminated, 1 unknown. 4 Phase 2, 3 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Lymphoma, B Cell: new trials by email Literature Review of Lymphoma, B Cell trials Research Report on Lymphoma, B Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Umoja Biopharma | 274 | 2026-11-01 | 2026-11-10 |
| Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma IL-2 pre-treated CD19 cells, IL-7/IL-15 pre-treated CD19 cells - Lymphoma, B Cell | Phase 4 | Unknown | jiangjingting | 10 | 2016-12-01 | 2016-12-14 |
| The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma KA2237 - Lymphoma, B Cell | Phase 1 | Completed | Karus Therapeutics Limited | 23 | 2016-07-01 | 2019-02-06 |
| DepoCyt for Active Lymphomatous or Leukemic Meningitis cytarabine liposome injection - Neoplastic Meningitis, Lymphoma, B Cell | Phase 2 | Terminated | Duke University | 4 | 2006-06-01 | 2013-06-17 |
| Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma high dose methotrexate, high dose cytarabine, radiotherapy - Lymphoma, B Cell | Phase 2 | Completed | International Extranodal Lymphoma Study Group (IELSG) | 79 | 2003-07-01 | 2015-03-30 |
| Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma rituximab, CHOP, intrathecal methotrexate - Lymphoma, B Cell | Phase 2 | Completed | International Extranodal Lymphoma Study Group (IELSG) | 64 | 2000-11-01 | 2009-07-22 |
| A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis intrathecal rituximab - Lymphoma, B Cell | Phase 1 | Withdrawn | International Extranodal Lymphoma Study Group (IELSG) | 2015-03-30 |
Lymphoma, B-Cell (7) · Leukemia (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Meningeal Carcinomatosis (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Lymphoma (6) · Lymphoma, Non-Hodgkin (6) · Central Nervous System Neoplasms (1) · Hematologic Diseases (1) · Meningeal Neoplasms (1) · Neoplasms by Site (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1)
Radiotherapy (2) · Cytarabine (1) · Methotrexate (1) · Rituximab (1) · Sirolimus (1)
International Extranodal Lymphoma Study Group (IELSG) (3) · Duke University (1) · Karus Therapeutics Limited (1) · Umoja Biopharma (1) · jiangjingting (1)
United States (3) · Switzerland (2) · China (1)
Andres JM Ferreri, MD (2) · Emanuele Zucca, MD (2) · Andreas Sarris, MD (1) · Annarita Conconi, MD (1) · David Rizzieri, MD (1) · Jingting Jiang, Professor (1) · Luke Walker, MD (1) · Mary Gospodarowicz, MD (1) · Michele Reni, MD (1) · Umberto Vitolo, MD (1)